Nothing Special   »   [go: up one dir, main page]

WO1998028038A1 - Procede et dispositif de regulation du cycle reproducteur des mammiferes - Google Patents

Procede et dispositif de regulation du cycle reproducteur des mammiferes Download PDF

Info

Publication number
WO1998028038A1
WO1998028038A1 PCT/US1997/023345 US9723345W WO9828038A1 WO 1998028038 A1 WO1998028038 A1 WO 1998028038A1 US 9723345 W US9723345 W US 9723345W WO 9828038 A1 WO9828038 A1 WO 9828038A1
Authority
WO
WIPO (PCT)
Prior art keywords
mammal
lhrh
period
electrotransport
agent
Prior art date
Application number
PCT/US1997/023345
Other languages
English (en)
Inventor
James B. Eckenhoff
Original Assignee
Alza Corporation
Eckenhoff, Bonnie, J.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corporation, Eckenhoff, Bonnie, J. filed Critical Alza Corporation
Priority to AU57065/98A priority Critical patent/AU5706598A/en
Publication of WO1998028038A1 publication Critical patent/WO1998028038A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/0436—Material of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir

Definitions

  • This invention relates to the controlled delivery of leutinizing hormone releasing hormone (LHRH) or an analog of LHRH by electrotransport to female animals, particularly female breeding animals, to control ovulation. More particularly, this invention relates to the transdermal electrotransport delivery of LHRH or an analog thereof to mares to control the time of birth of a colt.
  • LHRH leutinizing hormone releasing hormone
  • the ability to control an animal's date of birth is generally of importance in animal breeding. More particularly, the economic considerations surrounding the breeding of some species, e.g., thoroughbred race horses, have traditionally inspired creative scientific approaches to equine breeding.
  • the ability to accurately and precisely select equine birth dates is especially important in light of the official determination, by the breeder's association, of January 1 as the universal birth date of thoroughbred horses for racing purposes. That is, all horses born within a calendar year are presumed to have a January 1 birth date for racing purposes. Thus, animals born earlier within any given calendar year have a significant developmental advantage over those born later in the same year.
  • follicular development and the onset of ovulation are dependent on the presence of certain hormones, such as luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrogen, and progesterone (see, for example, D. Freeman et al., "Mare management", Large Animal Vet.: 6-8 (July/Aug., 1992)).
  • LH luteinizing hormone
  • FSH follicle-stimulating hormone
  • estrogen progesterone
  • Prostaglandin and its analogues have been delivered to mares to cause the regression of the corpus luteum, and to thereby attain a reduction of the estrous period.
  • Progesterone has also been delivered to either suppress or synchronize the heat periods in mares having long and erratic estrous cycles.
  • LHRH also known as gonadotropin releasing hormone or GnRH
  • FSH follicle-stimulating hormone
  • LHRH has been delivered to equines by various methods, including injection and implantation. For instance, LHRH has been delivered by intravenous and intramuscular injection in order to determine its effect on the release of luteinizing hormone (LH) and ovulation (see, J.E. Turner, "The Effect of Various Gonadotropin-releasing Hormone Regimes on Gonadotrophins, Follicular Growth and Ovulation in Deeply Anoestrous Mares", J. Reprod. Fert. Suppl. 44:213-225 (1991)).
  • LHRH has also been successfully delivered to mares from subcutaneously implanted osmotic minipumps, which are commercially available from ALZA Corporation, Palo Alto, California) to induce ovulation (see, C.G.V., Ainsworth, "Continuous Infusion of Gonadotropin-releasing Hormone (GnRH) Advances the Onset of Oestrous Cycles in Thoroughbred Mares on Australian Stud Farms", J. Reprod. Fert., Suppl 44:235-240 (1991)).
  • electrotransport refers generally to the passage of a substance through a body surface, such as skin, mucous membrane, or nails, induced at least partially by an electrical field.
  • a therapeutic agent may be introduced into an animal's body by one of several electrotransport processes.
  • One form of electrotransport called iontophoresis, involves the electrically induced transport of charged ions.
  • Another type of electrotransport, electroosmosis involves the movement of a liquid and all agents, including uncharged agents, dissolved therein under the influence of an electric field.
  • electroporation involves the transport of an agent through transiently-existing pores formed in the skin or other biological membranes by the application of an electric field.
  • electrotransport is used herein in its broadest possible meaning, which includes the electrically induced or enhanced transport of at least one agent, which may be charged, or uncharged, or mixtures thereof, regardless of the specific mechanism or mechanisms by which the agent is actually transported.
  • Sibalis U.S. Patents 5,013,293; 5,312,325 and 5,372,579 all disclose an electrolytic transdermal patch provided with a current oscillator for the periodic delivery of LHRH to induce or inhibit ovulation.
  • the patent teaches delivering "pulses" of electrotransport current, each pulse being about 6 minutes in duration, at a frequency of one 6 minute pulse per hour, to deliver LHRH to women in order to match the body's natural release of LHRH and thereby induce ovulation.
  • the delivery of LHRH at a frequency of two or more 6 minute pulses per hour is said to completely extinguish gonadotrophic secretion and inhibit ovulation (see, column 2, lines 44-57 and column 6, lines 16-30 of Sibalis U.S. 5,013,293).
  • This invention provides a method of controlling the estrous cycle, inducing ovulation during an anestrous period, and/or restarting the estrous cycle of a female mammal which is already experiencing some stage of the estrous cycle. This is attained by non-invasively and continuously delivering LHRH, or an analog thereof, to female mammals by transdermal electrotransport.
  • a substantially constant electrical potential is applied to deliver the LHRH across a body surface of the mammal. This electrical potential induces or enhances the transport of the LHRH through the body surface, preferably in a substantially continuous manner, and more preferably at a substantially constant rate.
  • the present invention can be used in the breeding of animals such as cattle and horses.
  • the invention may be used to ensure that one or more female breeding animals (eg, an entire herd) are ovulating at the same time so that the animals can be inseminated (ie, by artificial insemination) at the same time, thereby making the use of insemination materials and the scheduling of veterinary visits more efficient.
  • the invention has particular utility in controlling the ovulation of female thoroughbred race horses.
  • the hormone is continuously delivered by transdermal electrotransport to a female equine (mare) to induce ovulation at a time when the mare is normally in a seasonal anestrous period, after which the mare is naturally or artificially inseminated to achieve impregnation at a seasonal time which results in the colt being born soon after January 1.
  • the hormone is continuously delivered by transdermal electrotransport to female breeding animals (eg, cattle, sheep, pigs, etc) to induce ovulation at a time when the animal is normally in a seasonal anestrous period, after which the animals (eg, an entire head) are artificially inseminated to achieve impregnation.
  • Fig. 1 is a sectional view of one embodiment of a transdermal electrotransport device useful in accordance with the present invention.
  • Fig. 2 is a graph showing typical concentrations of selected hormones in the blood serum of a horse as a function of time during the horse's estrous cycle.
  • Fig. 3 is a graph showing blood progesterone and leuteinizing hormone (LH) levels in a mare participating in a clinical study described in Example 1.
  • Fig. 4 is a graph showing blood progesterone and leuteinizing hormone (LH) levels in another mare participating in the clinical study described in Example 1.
  • Fig. 5 is a graph showing blood progesterone and leuteinizing hormone (LH) levels in yet another mare participating in the clinical study described in Example 1.
  • Fig. 6 is a cross sectional view of the electrotransport delivery device used in the in vivo studies of Example 2 herein. MODES FOR CARRYING OUT THE INVENTION
  • LHRH includes all the natural and synthetic analogs and prodrugs (eg, esters) of LHRH, including LHRH and salts of LHRH, such as, gonadorelin acetate, eg. LUTREPULSE (sold by Ortho Pharmaceuticals, Raritan, N.J.); Cystorelin (sold by Abbott Laboratories, N. Chicago, IL); Hypocrine (sold by Tanabe Seiyaku Co., Ltd., Osaka, Japan); Lutrelef (sold by Ferring AB, Malmo, Sweden); LHRH acetate (eg, Ovarelin); LHRH hydrochloride (e.g.
  • the present invention provides for the non-invasive electrotransport delivery through a body surface (eg, skin of an animal) of LHRH in a substantially continuous manner in order to induce ovulation.
  • the LHRH is preferably delivered in a substantially continuous manner, and more preferably at a substantially continuous rate, over a period of time effective to induce ovulation.
  • This invention generally relates to a method of modulating the reproductive cycle of a female mammal by electrotransport administration, through a body surface of the mammal, of a composition comprising LHRH, in a substantially continuous manner, preferably, at a substantially constant rate.
  • the LHRH is administered over a period of time effective to induce ovulation.
  • the continuous administration of LHRH to a mammal in an estrous cycle over a predetermined number of days restarts ovulation without inhibiting the estrous cycle, as occurred with the pulsatile method of the prior art.
  • the LHRH is preferably continuously delivered by electrotransport for at least about 80%, preferably for at least about 90%, and more preferably for at least about 95% of the administration period. In some cases, the LHRH may be administered for about 98 to 99%, and even up to about 100% of the administration period.
  • the electrotransport delivery of LHRH generally produces increased secretion of luteinizing hormone (LH) and a corresponding increase in serum LH concentration within about 5 to 10 days after starting the administration.
  • the administration of the LHRH may be commenced during an estrous period to restart the estrous cycle at a predetermined time, generally about 3 to 7 days after commencement of delivery.
  • the administration of the agent may also be started within an anestrous cycle to start the estrous cycle at a predetermined time, generally about 3 to 7 days thereafter.
  • the rate of LHRH delivery remains, preferably, substantially constant over the administration period. This means that the amount of LHRH delivered through the body surface in any given unit of time, e.g., 1 hour, remains within about 30%, more preferably within about 20%, and still more preferably within about 10%, of the amount delivered in any other unit of time within the administration period. In some cases, the amount per unit time of LHRH delivered may even remain within about 5%, and even about 3 to 2% within the administration time period.
  • Another preferred embodiment of the method utilizes a substantially constant applied electric current. Since in this case, the electric current is applied substantially continuously, the delivery of LHRH through the selected body surface is assumed to occur substantially continuously, i.e., over at least about 80%, preferably at least about 90%, and more preferably at least about 95% of the administration period. In some cases, the current may even be applied substantially continuously at least about 98-99%, and even up to 100% of the delivery time. Thus, the agent is delivered in a substantially continuous manner and not as a pulse over a short period of time with long periods of time in-between, during which time no delivery is attained. In a most preferred embodiment, LHRH is delivered substantially without interruption during the entire extended delivery period.
  • a preferred rate of delivery of the agent is about 0.01 to 10 mg, and more preferably about 0.05 to 5 mg, over a period of about 1 to 10 days, or 500 ⁇ g/day to 10 mg/day, preferably 1 mg/day to mg/day and more preferably about 1 mg/day to 5 mg/day.
  • the administration of LHRH induces a first initial surge in the serum concentration of luteinizing hormone (LH) and a subsequent increase in follicle stimulating hormone (FSH), progesterone, and estradiol over the following 20 days, all of which are consistent with the induction of ovulation (see, Fig. 2).
  • FSH follicle stimulating hormone
  • estradiol estradiol
  • a second surge in LH serum concentration is attained, which is indicative of the initiation of an estrous cycle.
  • the method of this invention may be custom tailored to obtain any specific birth date, within some margin of error, by calculating back the starting date and period of delivery of LHRH. This may be done taking into consideration the desired birth date, the gestation period of the mammal, and the LHRH delivery period, generally about 1 to 10 days.
  • the present invention is applied to the breeding of horses, by administering LHRH to female equines for the improved breeding of horses, such as thoroughbred race horses.
  • This method is applied to preferably obtain birth dates as close, and subsequent, to January 1 of the following year as possible.
  • the preferred starting date and period of time for the electrotransport delivery of LHRH to thoroughbred mares are dependent on, and may be calculated, the desired birth date, preferably being as early as January 1 , but not before this date, the gestation period of the mare being usually about 335 to 340 days, and the period from initiation of the electrotransport delivery of LHRH to the optimal time for attempting insemination generally being about 5 to 20 days.
  • the continuous transdermal administration of the LHRH by electrotransport to mares for breeding thoroughbred horses may preferably occur from about, but not before, January 1 to March 30, more preferably from about January 5 to February 15, and most preferably from about January 15 to February 1.
  • the transdermal administration of LHRH by electrotransport may also be used to select a desired insemination date.
  • LHRH is electrotransported through a body surface of the mammal, e.g., the mare, while it experiences some stage of the estrous cycle. This procedure, restarts the estrous cycle of the mare, and is generally undertaken by substantially continuously delivering LHRH by electrotransport for a period of about 0.5 to 10 days, preferably about 1 to 7 days, and more preferably about 2 to 5 days. Over this period of time, the agent is generally delivered at a rate of about 0.05 to 15 micrograms per hour ( ⁇ g/hr), preferably about 1 to 10 ⁇ g/hr, and more preferably about 5 to 8 ⁇ g/hr.
  • the period and the rate of delivery of LHRH may be varied depending on a number of factors, including the weight of the mammal, e.g., the mare, and its reproductive stage at the time the treatment is started. Regardless of the stage of the estrous cycle, the electrotransport delivery of LHRH to the mammal for the described period of time at the described delivery rate causes the cycle to be started again. Thus, a mammal's cycle may be essentially reset or restarted at any given time by the initiation of electrotransport delivery of LHRH.
  • a date may be selected for its insemination by either artificial or natural means, and the initiation time of transdermal electrotransport of LHRH may be calculated based on the knowledge of the time from the initiation of the estrous cycle to the optimal time for insemination, typically about 5 to 20 days, and the time from initiation of LHRH electrotransport to the resetting of the estrous cycle, or about 3 to 7 days. For example, assuming that a male mammal, e.g., a stud, will be available on or about June 24, the optimal time to begin the electrotransport delivery of LHRH to the mare would be about June 10 to June 18. However, in some cases, the period may extend beyond these dates.
  • this controlled method of breeding entails first delivering LHRH by transdermal electrotransport to a mammal, such as a mare, over a predetermined period of time in a substantially continuous manner, and preferably at a substantially constant rate effective to induce ovulation.
  • a predetermined period of time is then allowed to pass from a date, which is a function of the dates of initiation or cessation of transdermal electrotransport, or both.
  • this predetermined period may be about 3 to 7 days after initiation of electrotransport delivery. In another embodiment, the period may be within about 2 days of cessation of LHRH electrotransport delivery.
  • an endogenous second surge of serum LH concentration generally occurs, which signals the initiation of a newly induced estrous cycle, from which the date of ovulation may be calculated as is known in the art.
  • the mare may be subsequently inseminated, either naturally or artificially, at a time expected to be most likely to achieve impregnation, time which clearly overlaps with the ovulation date, as is known in the art.
  • the delivery of LHRH according to the present invention may be accomplished by a number of electrotransport devices.
  • One example of an electrotransport device useful for the practice of the present invention is illustrated in Fig. 1.
  • Device 10 has two current distributing members or electrodes, comprised of electrically conductive materials, referred to herein as a donor electrode 12 and a counter electrode 14.
  • the electrodes may be composed of any materials which are sufficiently electrically conductive including, without limitation thereto, silver, silver chloride, zinc, carbon, platinum, and stainless steel.
  • the electrodes may be provided in a variety of forms including metal foil, screen, coatings or polymer/metal composites. The composites may be formed by numerous processes such as extrusion, calendering, film evaporation, or spray coating.
  • the donor and counter electrodes 12 and 14 are positioned adjacent to, and in electrical contact with, the donor reservoir 16 and the counter reservoir 18, respectively.
  • the donor reservoir 16 contains the LHRH to be delivered, preferably in the form of an aqueous solution of a water soluble salt of LHRH.
  • the counter reservoir 18 may contain a biocompatible electrolytic salt such as sodium chloride or another agent to be delivered.
  • the reservoirs are formed of any material adapted to absorb and hold a sufficient quantity of liquid therein in order to permit transport of LHRH/electrolyte therethrough by electrotransport.
  • the reservoirs 16 and 18 are formed of one or more hydrophilic polymers such as polyvinylpyrrolidone, polyvinyl alcohol, and/or polyethylene glycols and optionally also contain one or more hydrophobic polymers such as polyisobutylene, polyethylene, or polypropylene.
  • An electrical insulator 20 is positioned between (i) the donor electrode 12 and donor reservoir 16 and (ii) the counter electrode 14 and counter reservoir 18. Insulator 20, which may be an air gap or may be composed of a material which conducts neither electrons nor ions to a substantial extent, prevents device 10 from short-circuiting through a path which does not include the body surface 40 to which the device 10 is applied.
  • the device 10 optionally includes a backing layer 22 composed of a liquid impermeable non-conducting material.
  • Device 10 has an electronic circuit, illustrated schematically in Fig. 1 as layer 24, having therein a power source, preferably a DC source, e.g., one or more batteries.
  • a power source preferably a DC source
  • the electronic circuit layer 24 may be comprised of electronically conductive pathways printed, painted or otherwise deposited on a thin, flexible substrate such as, for example, a film or polymeric web, e.g. the electronic circuit layer 24 is a flexible printed circuit.
  • the electronic circuit layer 24 may also include one or more electronic components which control the level, wave form shape, polarity, timing, etc, of the electric current applied by device 10.
  • the circuit layer 24 may contain one or more of the following electronic components: control circuitry such as a current controller, e.g.
  • the outputs of the circuit layer 24 are electrically connected to the electrodes 12 and 14 such that each electrode is in electrical contact with an opposite pole of the power source within the circuit layer 24.
  • the device adheres to the body surface in this embodiment by means of a peripheral adhesive layer 28.
  • the device may contain an in- line adhesive layer, i.e. an adhesive layer positioned between reservoir 16 and/or 18 and the body surface of the patient.
  • An in-line adhesive must be composed of an ion-transmitting material, i.e. LHRH must be capable of penetrating the adhesive layer to reach the body surface.
  • Optional flux control membranes 30 and 32 are positioned between the donor reservoir 16 and the body surface 40 and between the counter reservoir 18 and the body surface 40, respectively, in order to limit or control the amount of passive, i.e. not electrically assisted, flux of LHRH to the body surface 40.
  • the device 10 of Fig. 1 is merely one example of an electrotransport device useful in accordance with present invention.
  • the system may contain other features, such as a removable protective liner (not shown) on the body surface contacting face 32 of the device.
  • certain components in the device 10 are unnecessary or optional according to the present invention.
  • the counter reservoir 18, the passive flux control membranes 30 and 32, and the peripheral adhesive 28 are all examples of optional components. If the materials of electrodes 12 and 14 form a galvanic couple, the independent power source in layer 24 may also become an optional component.
  • the device 10 of Figure 1 is presented solely for illustration of one embodiment of the present invention.
  • LHRH may be electrotransported through many locations, or body surfaces, on a mammal, such as an equine.
  • an electrotransport device may be affixed to the underside of an animal between the front and hind legs.
  • a device may be located on the interior of a leg, preferably a hind leg because of the larger surface area. Both the interior leg and underside locations are difficult for an animal, such as a horse, to reach.
  • the delivery of LHRH from an electrotransport device is preferably accomplished through an area of the neck of the mammal, which is preferred because it is very difficult for the animal to bite, scratch with its legs, or swat with its tail.
  • the application of an electrotransport device to the neck of a mammal is safer and more convenient for the preparation of the application site, i.e. shaving an area of the horse's neck so that the device may be applied directly to the skin.
  • an area of the underside located between the front and back legs may be utilized, the area is shaven, and an electrotransport device is applied thereto.
  • the agent may be administered through an area of the neck of the mammal, which also requires shaving prior to application of the device.
  • the selected body surface Prior to applying the device, the selected body surface may be advantageously treated or otherwise prepared to be most suitable for enhancing the delivery rate of the agent.
  • known electrotransport permeation enhancers such as alcohols, may be utilized in practicing the invention described herein.
  • the animal's hair is preferably removed from the selected body surface, e.g. by shaving. Hair removal allows the electrodes of the device to be placed in better ion transmitting relation with the skin surface (eg, skin) and also better permits the device to be adhered to the body surface (eg, skin).
  • the mares were prepped on the inner thigh of the hind leg with #20 clipper blade and wiped down with isopropyl alcohol.
  • An active, 2 cm 2 electrotransport-LHRH patch was applied to each mare on Day 1 of the study.
  • the patches delivered LHRH for 24 hours. New sites were prepped each day of application and a new patch was applied to each mare throughout the three day wearing period. Spent patches, from each 24 hours of wearing, were stripped following application of the new patch.
  • Blood samples were drawn at 24 hours prior to the start of LHRH delivery, and at 0, 0.5, 1.5, 3, 4.5, 6, 8, and 24 hours of treatment for each day of application through the three days of LHRH delivery. Twenty-four hour blood samples were then drawn on Days 4, 5, 6, and 7. Blood samples were then drawn at 0, 0.5, 1.5, 3, 4.5, and 6 hours of Day 21 of the study to conclude the study.
  • Figs. 3, 4, and 5 show progesterone and LH plasma concentrations of the three mares during the pretreatment, treatment and washout phases.
  • progesterone The plasma concentrations of progesterone (mg/mL) showed a distinct increase on Day 3 of treatment in mare A and were elevated on Days 4 through 7 in mares A and C. In mare B, progesterone concentrations were consistent during the seven days of the feasibility study and on Day 21.
  • the plasma concentrations of luteinizing hormone (mlU/mL) were increased above the normal range throughout the period of treatment (Days 1 through 7) in mare B, and on Days 2 through 6 in mares A and C. The increased concentrations of LH were most consistent on Days 4, 5, and 6 (except in mare C).
  • plasma luteinizing hormone concentrations were generally ⁇ 1.0 mlU/mL. Increased concentrations refer to concentrations >1.5 mlU/mL
  • Mares A and C showed the signs of coming into season. These two mares stood for the teaser stallion on Day 6; whereas, mare B did not show this behavior. These physiological observations are consistent with the blood results obtained in the study for mares A and C which wore the patches for two sequential 24 hour periods.
  • Thirty electrotransport delivery devices were produced having the construction illustrated, in exploded view, in Fig. 6, fifteen of the devices having a 1 cm 2 area and 15 having a 2 cm 2 area.
  • the current density used was 0.1 mA/cm 2
  • the total current for the 1 cm 2 device was a 0.1 mA while the total current for the 2 cm 2 device was 0.2 mA.
  • Double sided adhesive foam tape having a thickness of 0.8 mm (1/32 in.) was folded over on itself to create a foam layer 302 having a thickness of 1.6 mm (1/16 in.). Then, by use of a NAFE punch press, openings 304, 306 were punched out with the die. Gel reservoirs 308, 310 having the same composition as the cathodic hydrogels described in Example 1 were inserted into the openings 304, 306.
  • a silver foil anodic electrode 312 was placed over the gel 310 and a silver chloride-loaded ethylene vinyl acetate film electrode 314 was placed over gel 308.
  • the electrodes 312, 314 were electrically connected to the outputs 315a, 315b of a printed circuit board assembly 316 by means of electrically conductive adhesive strips 318a, 318b (Arclad 8001 , Adhesives Research, Allentown, PA), respectively.
  • the top of the circuit board assembly 316 was Medpar pigmented film 320 (3M Company, St. Paul, MN).
  • the skin side of gel 310 was covered with an anion exchange membrane 322 (Sybron MA 3475, The Electrosynthesis Co., E. Amherst, NY) which is impermeable to cations.
  • a layer 324 of single sided adhesive foam had an opening 326 punched out using the punch press.
  • a LHRH-containing gel reservoir 328 having the same composition as the anodic hydrogel described in Example 1 was inserted into the opening 326.
  • the openings 310 and 326 had the same cross-sectional size and shape so they were aligned on top of one another, with the anion exchange membrane 322 sandwiched therebetween.
  • a 0.03 mm (1 mil) thick silicone coated polyester release liner 330 was placed over the skin-contacting surfaces of the device until use.
  • the circuit board assembly applied electrotransport currents of 0.1 mA or 0.2 mA, depending upon the cross-sectional areas of gels 308, 310 and 328. For those devices having gels with a cross-sectional area of 2 cm 2 , the applied current was 0.2 mA. For those devices having gels with a cross- sectional area of 1 cm 2 , the applied current was 0.1 mA. Thus, the applied current density was 0.1 mA/cm 2 for all systems.
  • a blood sample was taken from each mare 24 hours prior to application of the device to establish a pretreatment baseline. During the 5 day application period, blood samples were taken daily at 2 hrs, 6 hrs, and 24 hrs, from the time of initial application of the device.
  • Progesterone was determined by an ELISA (Enzyme Linked Imuno-Sorbent Assay), and the levels of luteinizing hormone (LH), follicle- stimulating hormone (FSH), and estradiol were determined by radioimmunoassays.
  • Table 1 below shows the serum levels of LH for each mare from day -1 to day 20 of the study period.
  • the serum concentrations of FSH (mlU/ml), progesterone (ng/ml), and estradiol (pg/ml) were also obtained for mares 1 to 5 and 7 to 12 as a function of the day relative to the initiation of the electrotransport treatment.
  • Mares 1 to 5 and 7 to 12 were rectally examined by a veterinary surgeon to determine the stage of their estrous cycle.
  • the rectal examinations were performed prior to the electrotransport LHRH treatment described above and on days 3, 5, 8, 10, 13, 15, 17 and 20.
  • Table 3 below shows the observations made 1 day prior to starting treatment.
  • Table 3 below shows the observations made on day 15 after starting treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne un procédé d'apport, par électrotransport sensiblement continu d'hormone libérant l'hormone lutéinisante (LHRH), de prologues, d'analogues, de sels ou de mélanges de celle-ci, de préférence à une vitesse sensiblement constante, à un mammifère femelle en vue de modifier son cycle reproducteur. Un dispositif d'électrotransport est conçu pour apporter en continu et sur une longue durée des prologues, des analogues de LHRH, des sels ou des mélanges de ces derniers à un mammifère. Cette technologie peut être appliquée avec succès pour la sélection contrôlée de mammifères tels que les chevaux de race thoroughbred (pur sang anglais).
PCT/US1997/023345 1996-12-24 1997-12-17 Procede et dispositif de regulation du cycle reproducteur des mammiferes WO1998028038A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU57065/98A AU5706598A (en) 1996-12-24 1997-12-17 Method and device for controlling mammalian reproductive cycle

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3406596P 1996-12-24 1996-12-24
US60/034,065 1996-12-24

Publications (1)

Publication Number Publication Date
WO1998028038A1 true WO1998028038A1 (fr) 1998-07-02

Family

ID=21874089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/023345 WO1998028038A1 (fr) 1996-12-24 1997-12-17 Procede et dispositif de regulation du cycle reproducteur des mammiferes

Country Status (3)

Country Link
AU (1) AU5706598A (fr)
FR (1) FR2757401B1 (fr)
WO (1) WO1998028038A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465709B1 (en) 1999-07-08 2002-10-15 Johnson & Johnson Consumer Companies, Inc. Exothermic bandage
US6890553B1 (en) 1999-07-08 2005-05-10 Johnson & Johnson Consumer Companies, Inc. Exothermic topical delivery device
US7113821B1 (en) 1999-08-25 2006-09-26 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery
US7133717B2 (en) 1999-08-25 2006-11-07 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery and diagnostic sampling
US7404815B2 (en) 2000-05-01 2008-07-29 Lifescan, Inc. Tissue ablation by shear force for sampling biological fluids and delivering active agents
WO2013166298A3 (fr) * 2012-05-04 2014-08-21 Ethicon-Endo Surgery, Inc. Timbre médical transdermique
US9888932B2 (en) 2004-01-30 2018-02-13 Vaxxas Pty Limited Method of delivering material or stimulus to a biological subject
US9943673B2 (en) 2010-07-14 2018-04-17 Vaxxas Pty Limited Patch applying apparatus
US10022322B2 (en) 2007-12-24 2018-07-17 Vaxxas Pty Limited Coating method
US11103259B2 (en) 2015-09-18 2021-08-31 Vaxxas Pty Limited Microprojection arrays with microprojections having large surface area profiles
US11147954B2 (en) 2015-02-02 2021-10-19 Vaxxas Pty Limited Microprojection array applicator and method
US11175128B2 (en) 2017-06-13 2021-11-16 Vaxxas Pty Limited Quality control of substrate coatings
US11179553B2 (en) 2011-10-12 2021-11-23 Vaxxas Pty Limited Delivery device
US11254126B2 (en) 2017-03-31 2022-02-22 Vaxxas Pty Limited Device and method for coating surfaces
US11464957B2 (en) 2017-08-04 2022-10-11 Vaxxas Pty Limited Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (MAP)
US12090295B2 (en) 2015-09-28 2024-09-17 Vaxxas Pty Limited Microprojection arrays with enhanced skin penetrating properties and methods thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860701A (en) * 1968-04-22 1975-01-14 Searle & Co Method for use and compositions of 11-lower alkyl steroids and drug delivery system for the controlled elution of 11-lower alkyl steroids
US5013293A (en) 1987-05-28 1991-05-07 Drug Delivery Systems Inc. Pulsating transdermal drug delivery system
WO1993003790A1 (fr) * 1991-08-26 1993-03-04 Rutgers, The State University Of New Jersey Procede et dispositif ionotherapeutiques
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581544B1 (fr) * 1985-05-10 1989-11-03 Univ Melbourne Procede pour provoquer une ovulation chez les juments et vehicule pharmaceutique associe

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860701A (en) * 1968-04-22 1975-01-14 Searle & Co Method for use and compositions of 11-lower alkyl steroids and drug delivery system for the controlled elution of 11-lower alkyl steroids
US5013293A (en) 1987-05-28 1991-05-07 Drug Delivery Systems Inc. Pulsating transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5372579A (en) 1987-05-28 1994-12-13 Drug Delivery Systems, Inc. Pulsating transdermal drug delivery system
WO1993003790A1 (fr) * 1991-08-26 1993-03-04 Rutgers, The State University Of New Jersey Procede et dispositif ionotherapeutiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.E.TURNER,C.H.G.IRVINE: "The effect of various gonadotrophin-releasing hormone regimens on gonadotrophins,follicular growth and ovulation in deeply anoestrous mares", JOURNALS OF REPRODUCTION & FERTILITY LTD, vol. 44, 1991, GREAT BRITAIN, pages 213-213 - 225, XP002064443 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465709B1 (en) 1999-07-08 2002-10-15 Johnson & Johnson Consumer Companies, Inc. Exothermic bandage
US6890553B1 (en) 1999-07-08 2005-05-10 Johnson & Johnson Consumer Companies, Inc. Exothermic topical delivery device
US7113821B1 (en) 1999-08-25 2006-09-26 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery
US7133717B2 (en) 1999-08-25 2006-11-07 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery and diagnostic sampling
US7404815B2 (en) 2000-05-01 2008-07-29 Lifescan, Inc. Tissue ablation by shear force for sampling biological fluids and delivering active agents
US11207086B2 (en) 2004-01-30 2021-12-28 Vaxxas Pty Limited Method of delivering material or stimulus to a biological subject
US9888932B2 (en) 2004-01-30 2018-02-13 Vaxxas Pty Limited Method of delivering material or stimulus to a biological subject
US10751072B2 (en) 2004-01-30 2020-08-25 Vaxxas Pty Limited Delivery device
US10022322B2 (en) 2007-12-24 2018-07-17 Vaxxas Pty Limited Coating method
US9943673B2 (en) 2010-07-14 2018-04-17 Vaxxas Pty Limited Patch applying apparatus
US11179553B2 (en) 2011-10-12 2021-11-23 Vaxxas Pty Limited Delivery device
WO2013166298A3 (fr) * 2012-05-04 2014-08-21 Ethicon-Endo Surgery, Inc. Timbre médical transdermique
US9402999B2 (en) 2012-05-04 2016-08-02 Ethicon Endo-Surgery, Inc. Transdermal medical patch
US11147954B2 (en) 2015-02-02 2021-10-19 Vaxxas Pty Limited Microprojection array applicator and method
US11103259B2 (en) 2015-09-18 2021-08-31 Vaxxas Pty Limited Microprojection arrays with microprojections having large surface area profiles
US11653939B2 (en) 2015-09-18 2023-05-23 Vaxxas Pty Limited Microprojection arrays with microprojections having large surface area profiles
US12090295B2 (en) 2015-09-28 2024-09-17 Vaxxas Pty Limited Microprojection arrays with enhanced skin penetrating properties and methods thereof
US11254126B2 (en) 2017-03-31 2022-02-22 Vaxxas Pty Limited Device and method for coating surfaces
US11175128B2 (en) 2017-06-13 2021-11-16 Vaxxas Pty Limited Quality control of substrate coatings
US11828584B2 (en) 2017-06-13 2023-11-28 Vaxxas Pty Limited Quality control of substrate coatings
US11464957B2 (en) 2017-08-04 2022-10-11 Vaxxas Pty Limited Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (MAP)

Also Published As

Publication number Publication date
FR2757401B1 (fr) 2004-07-23
AU5706598A (en) 1998-07-17
IE970851A1 (en) 1998-07-01
IE20050176A1 (en) 2005-05-04
FR2757401A1 (fr) 1998-06-26

Similar Documents

Publication Publication Date Title
WO1998028038A1 (fr) Procede et dispositif de regulation du cycle reproducteur des mammiferes
US5941844A (en) Method and device for controlling mammalian reproductive cycle
KR940006528B1 (ko) 이온침투요법중에 전극을 재생하는 방법 및 장치
Jacobs et al. Comparative aspects of the healing of excisional wounds on the leg and body of horses
KR100453132B1 (ko) 경피 약제 플럭스를 향상시키기 위한 장치 및 방법
US6001088A (en) Iontophoresis method and apparatus
Ledger Skin biological issues in electrically enhanced transdermal delivery
EP0429842B1 (fr) Dispositif d'administration transcutanée de médicaments à base de protéine ou de peptide
Kanikkannan Iontophoresis-based transdermal delivery systems
Slimp et al. Heterosexual, autosexual and social behavior of adult male rhesus monkeys with medial preoptic-anterior hypothalamic lesions
US8295924B2 (en) Transdermal systems for the delivery of ionic agents directly to open wounds and surgically repaired incisions
JP2003522613A (ja) 交流を用いて物質を抽出する方法
EP0934097B1 (fr) Systeme d'apport de medicament par ionophorese et procede de mise en oeuvre associe
DeBold et al. Sexual receptivity: Brain sites of estrogen action in female hamsters
Zakzewski et al. Transdermal delivery of regular insulin to chronic diabetic rats: effect of skin preparation and electrical enhancement
Napoli et al. Hormonal induction of behavioral estrus modified by electrical stimulation of hypothalamus
IE84096B1 (en) Method and device for controlling mammalian reproductive cycle
IE84415B1 (en) Device for controlling mammalian reproductive cycle
JP4072268B2 (ja) 皮膚吸収型薬液投与装置
Bruhn et al. Ontogeny of hypothalamus-pituitary function in the fetal pig: gonadotropin release in response to electrical and electrochemical stimulation of the hypothalamus
KR0151135B1 (ko) 가축병 치료용 약물을 투여하는 장치
GB1588933A (en) Dressings for use on a mammalian body and capable of forming a galvanic couple therewith
US7105487B2 (en) Method for inducing onset of the reproductive cycle of female breeding animals
WO2000025762A1 (fr) Dispositif pour une therapie combinee transdermique et phonophoretique et son utilisation dans un procede medical
Ca et al. Blockade of ovulation and release of LH in the rat by electrochemical stimulation of the frontal lobe cortex

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase